Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

Inclusion Criteria at Baseline: * Male or female renal allograft recipients at least 18 years old. * Written informed consent. * Patient receiving a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor. * Cold ischemia time (CIT) \< 24 hours. * Negative pregnancy test for female patients. Inclusion Criteria at Randomization: * Patients on CNI (TAC or CsA) + Myfortic + steroids. * Serum creatinine \< 2.8 mg/dL (250 µmol/L) and an actual eGFR (MDRD4) ≥ 25 mL/min/1.73m exp2 (without renal replacement therapy). Exclusion Criteria at Baseline: Patients fulfilling any of the following criteria are not eligible for inclusion in this study: * Recipient of multiple organ transplants. * Recipient of ABO incompatible allograft or a positive cross-match. * Panel Reactive Antibodies (PRA) level ≥ 30 %. * Positive test for human immunodeficiency virus (HIV). * Patient receiving an allograft from a Hepatitis B surface Antigen (HBsAg) or a Hepatitis C Virus (HCV) positive donor. * HBsAg and/or a HCV positive patient with evidence of elevated LFTs (ALT/AST levels ≥ 2.5 times ULN). * Severe restrictive or obstructive pulmonary disorders. * Patient with severe allergy requiring acute or chronic treatment or hypersensitivity to any of the study drugs or similar drugs. * Severe hypercholesterolemia or hypertriglyceridemia. * Low platelet count. * Low white blood cell count. * History of malignancy of any organ system Exclusion Criteria at Randomization: * Graft loss. * Patient on renal replacement therapy. * Patient who experienced severe humoral and/or cellular rejection (BANFF ≥ IIb). * Patient with ≥ 2 episodes of AR or an AR episode that needed antibody treatment. * Patient with ongoing or currently treated AR (2 weeks prior to randomization). * Proteinuria \> 1 g/day. * Patients with recurrence of Focal Segmental Glomerulosclerosis (FSGS). * Low platelet count; Low white blood cell count; Low absolute neutrophil count; Low hemoglobin. * Severe liver disease. * Systemic infection requiring continued therapy that would interfere with the objectives of the study. * Severe hypercholesterolemia or hypertriglyceridemia. * Patients with ongoing wound healing problems, clinically significant infection requiring continued therapy. * Presence of intractable immunosuppressant complications or side effects. * Patients on anticoagulants that prevents renal allograft biopsy. * Use of prohibited medication. * Use of immunosuppressive agents not utilized in the protocol. * Pregnant or nursing (lactating) women. * Women of child-bearing potential not using a highly effective method of birth control.